Intellia Therapeutics Inc (NASDAQ:NTLA) shares hit a new 52-week low on Thursday . The stock traded as low as $18.42 and last traded at $18.56, with a volume of 109,432 shares trading hands. The stock had previously closed at $18.82.

Several research analysts have weighed in on NTLA shares. Leerink Swann started coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They issued a “market perform” rating and a $32.00 target price on the stock. Credit Suisse Group AG started coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They issued an “outperform” rating and a $39.00 target price on the stock. Wedbush started coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They issued an “outperform” rating and a $38.00 target price on the stock. Finally, Jefferies Group started coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They issued a “hold” rating and a $33.00 target price on the stock.

The firm’s market capitalization is $658.37 million. The company’s 50 day moving average is $25.32 and its 200-day moving average is $25.42.

In other Intellia Therapeutics news, insider Bros. Advisors Lp Baker purchased 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 11th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $3,600,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Carl L. Gordon purchased 250,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 11th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $4,500,000.00. The disclosure for this purchase can be found here.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.